Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Achalasia

    Current Location

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      10 Achalasia Trials Near You

      Power is an online platform that helps thousands of Achalasia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Botox vs. Pyloromyotomy for Esophageal Cancer Surgery

      Cleveland, Ohio
      The goal of this pragmatic, registry-based, randomized clinical trial is to find out if using botulinum toxin (Botox) to help drain the stomach during an esophagectomy works as well as a pyloromyotomy in patients undergoing elective esophagectomy for benign or malignant esophageal disease. Both methods are intended to prevent problems with food emptying too slowly from the stomach (delayed gastric emptying), which can cause discomfort after surgery. The main question it aims to answer is: Is intrapyloric Botox injection as a drainage procedure during esophagectomy non-inferior in preventing symptoms of delayed gastric emptying at 6 months postoperatively compared to pyloromyotomy? Researchers will compare intrapyloric Botox injection to pyloromyotomy to see if Botox is non-inferior to pyloromyotomy in easing symptoms of delayed gastric emptying. Participants will: Be randomized to one of two treatment groups-either intrapyloric Botox injection or pyloromyotomy-during their esophagectomy. Complete surveys assessing digestive symptoms at standard postoperative follow-up intervals (3 months, 6 months, 1 year, and 2 years postoperatively). Undergo a standard gastric emptying study at 6 months after surgery.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Neuromuscular Disease, Pregnancy, Allergy, Others

      170 Participants Needed

      HRM, FLIP, and Prucalopride for Dysphagia

      Chicago, Illinois
      Swallowing difficulties are extremely common and result in substantial morbidity, reduction in the quality of life, and mortality related to malnutrition and complications from regurgitation and aspiration. Unfortunately, our understanding regarding the pathophysiology of dysphagia and GERD has been hampered by focusing predominantly on circular muscle activity and ignoring the essential biomechanical properties of the esophageal wall that promote normal emptying. Our initial work explored the relationship between intrabolus pressure (IBP) and esophagogastric junction (EGJ) compliance as a metric for outflow resistance. This work highlighted the direct relationship between IBP and EGJ opening and was the foundation for the development of the classification scheme utilized around the world to diagnose esophageal motor disorders: "the Chicago Classification" (CC). Despite this improved understanding focused on bolus transit dynamics, there are still significant gaps in our scientific understanding centered on the lack of a true correlate for symptoms, reliable predictive models and effective treatments for Functional dysphagia, IEM and EGJOO. Given these limitations, we have developed novel approaches that combine assessments of primary and secondary peristalsis (a NeuroMyogenic Model of esophageal function). These will leverage our recent findings supporting the importance of the esophageal response to distension in bolus clearance, noting that this response of the esophageal wall to bolus retention or reflux is one of the most essential functions of the esophagus in preventing complications of aspiration, or reflux injury. We will also include an assessment of esophageal geometry and wall biomechanics (elasticity/dilatation) as these carry essential interactions with esophageal function that are overlooked in the current diagnostic paradigms. In order to test our hypothesis that wall mechanics are a major determinant of esophageal diseases, we had to develop new approaches and new technology to directly measure mechanical wall state, descending inhibition and LES opening. Using impedance techniques combined with manometry, we are now capable of assessing IBP and diameter changes across a space-time continuum (4D HRM). We also developed physics-based hybrid diagnostics that include a FLIP technique to assess esophageal work and power during volumetric distention (FLIP-MECH) and a fluoroscopy approach that simultaneously assesses esophageal diameter-pressure relationships (Fluoro-MECH). We also developed a new approach, Interactive FLIP Panometry, which facilitates an assessment of descending inhibition and the mechanism behind impaired LES opening. These tools will allow us to expand our models to combine an assessment of neuromyogenic function simultaneously with geometry. Our overarching goal will be to study well-defined patient populations (Functional Dysphagia, IEM/GERD, EGJOO and Achalasia) before and after targeted interventions to test the NeuroMyogenic and MechanoGeometric Model. This work will build upon the previous success of the CC and help advance the evolution of the CC by defining new, relevant biomechanical physiomarkers of disease activity that can identify new targets for therapeutic intervention and facilitate prediction of clinical outcomes.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Esophagitis, Barrett's Metaplasia, Others
      Must Not Be Taking:Anticoagulants

      575 Participants Needed

      Botox and/or Esophageal Dilation for Achalasia

      Nashville, Tennessee
      This trial is testing a combination of esophageal stretching and botox injections for patients with achalasia who have other health issues. The treatment aims to make swallowing easier by both stretching the esophagus and relaxing its muscles. Botox injections have been used for treating achalasia and other esophageal motility disorders, providing temporary relief.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Under 18, Previous Reflux Surgery, Others

      50 Participants Needed

      Valacyclovir + Shingrix for Achalasia

      Nashville, Tennessee
      Varicella zoster virus (VZV) is the cause of chickenpox and shingles, but it also infects, becomes latent, and reactivates in nerve cells of the bowel to cause a gastrointestinal disorder ("enteric shingles"). The Investigators recently found that a chronic active VZV infection, a form of enteric shingles, is associated with achalasia, a severe disease in which the passage of food from esophagus to stomach is impaired. We now propose to eradicate VZV to determine whether its association with achalasia is causal, to identify the genetic basis behind VZV reactivation in the esophagus, and the relationship of mast cells to enteric shingles and abdominal pain.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Unstable Illness, Neurologic Impairment, Others
      Must Be Taking:Valacyclovir, Shingrix

      40 Participants Needed

      POEM-F for Achalasia

      Baltimore, Maryland
      Per-oral endoscopic myotomy (POEM) has emerged as the endoscopic treatment of choice for achalasia, offering comparable symptom relief with laparoscopic Heller's cardiomyotomy. The main concern with POEM is the higher incidence of post-procedure gastroesophageal reflux disease (GERD), occurring in up to 50-60% of patients. In order to reduce the risk of GERD, endoscopic fundoplication has been developed as a novel procedure mimicking surgical anterior partial fundoplication that can be performed in the same session as POEM (POEM-F). Case series of POEM-F in patients with achalasia reported encouraging outcomes of low GERD rate of \~12% at 1 year. Prospective comparative data between POEM-F and conventional POEM on post-procedure GERD is current lacking. The investigators therefore designed an international multicenter prospective randomized study to investigate the efficacy of POEM-F. The investigators postulate that POEM-F could reduce the incidence of post-procedure GERD when compared with conventional POEM. This is an international multicenter randomized controlled trial conducted between high volume expert centers from Hong Kong SAR, China, India and United States of America. Adult patients with manometry confirmed achalasia would be randomised to undergo POEM-F or POEM. The procedure would be performed by experts with vast experience in POEM. The primary outcome is the incidence of post-procedure GERD at 1 year, defined by the updated Lyon consensus. Secondary outcomes include technical and clinical success rates, adverse events, post-POEM endoscopic and manometry findings as well as patients' symptom scores. Sample size calculation Based on existing pilot comparative data on POEM-F and POEM, it is estimated that 84 patients would be required to demonstrate a difference in post-procedure GERD of 47.6% to 18.2%, with 80% power and false positive rate of 0.05, accounting for 10% loss to follow-up. Purpose and potential The current study proposal could demonstrate the superiority of POEM-F over POEM in reducing post-procedural GERD. It would also demonstrate the safety and reproducibility of the technique in expert centers across the globe. It could potentially replace conventional POEM as the preferred minimally invasive endoscopic treatment for achalasia.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Previous Esophageal Surgery, Obesity, Pregnancy, Others

      81 Participants Needed

      Diagnostic Methods for Achalasia

      Atlanta, Georgia
      This trial uses a new technology to map the lower esophageal sphincter in patients with achalasia. It helps doctors understand if the problem is due to muscle stiffness or nerve issues, allowing for earlier and better treatment. EsoFLIP is a new technology used for esophageal dilation in achalasia.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Prisoners, Cardiac Disease, Others

      80 Participants Needed

      Per-Oral Endoscopic Myotomy (POEM) for Achalasia

      Dallas, Texas
      This trial studies a procedure using an endoscope to cut certain muscles in the esophagus. It targets people with achalasia who have trouble swallowing. The treatment aims to reduce swallowing problems without causing much acid reflux. This procedure was first attempted by Inoue for the treatment of achalasia in humans.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      20 Participants Needed

      RFA Knife for POEM in Esophageal Disorders

      Houston, Texas
      This trial is testing a new surgical tool called the Speedboat-RSD knife for patients with esophageal muscle issues. The tool aims to make the procedure faster and less painful by combining cutting and bleeding control in one device. The Speedboat-RS2 (Creo-Medical, UK) is a novel device which has shown promising results for similar procedures.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      105 Participants Needed

      Sling-Fiber Preservation vs. Conventional POEM for Achalasia

      Orange, California
      Peroral endoscopic myotomy (POEM) is an effective, minimally invasive treatment for achalasia, offering excellent rates of symptom relief. However, a significant drawback is the high incidence of gastroesophageal reflux disease (GERD) following the procedure. One proposed technical modification, the selective preservation of the sling fibers during gastric myotomy (SFP-POEM), may reduce this risk without compromising efficacy as compared to a conventional POEM procedure, which includes myotomy of the sling fibers. In this study, adults with achalasia will be randomly assigned to receive one of the two POEM technical approaches. Researchers will monitor whether preserving sling fibers reduces the rates of reflux esophagitis (classified as Los Angeles Grade B or higher) on follow-up endoscopy. Participants will be followed for up to 1 year after the procedure.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Spastic Motility Disorders, Sigmoid Esophagus, Prior Surgical Myotomy, Others

      120 Participants Needed

      Endoscopic Therapy for Esophageal Achalasia

      Sacramento, California
      Evaluation of current and newly developed endoluminal therapies in the management of Upper and Lower GI conditions.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Adults Unable To Consent, Others

      500 Participants Needed

      Why Other Patients Applied

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51
      Match to a Achalasia Trial

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial
      Search
      Achalasia
      Show Map
      Map View
      Your Location

      Frequently Asked Questions

      How much do Achalasia clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Achalasia clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Achalasia trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Achalasia is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Achalasia medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Achalasia clinical trials?

      Most recently, we added Sling-Fiber Preservation vs. Conventional POEM for Achalasia, Botox vs. Pyloromyotomy for Esophageal Cancer Surgery and HRM, FLIP, and Prucalopride for Dysphagia to the Power online platform.

      What is the treatment of choice for achalasia?

      The main aim in achalasia is to loosen the tight muscle at the stomach entrance; today the most durable ways to do this are a minimally-invasive “muscle-cutting” operation—laparoscopic Heller myotomy with a small anti-reflux wrap—or its endoscopic cousin, POEM, both of which give long-lasting relief in 85-90 % of patients. Graded pneumatic (balloon) dilation remains a good non-surgical alternative when a myotomy is not available or a patient is unfit for anesthesia, while Botox injections or medicines are usually reserved for people who cannot undergo either of these approaches.

      Is achalasia cancerous?

      Achalasia is a benign swallowing disorder, not a cancer. Because food can stagnate and inflame the esophagus, long-standing achalasia raises the risk of esophageal cancer several-fold, but the absolute chance remains low (well under 1% for most people). After about 10 years of disease, talk with your gastroenterologist about periodic endoscopy and seek prompt evaluation if swallowing suddenly worsens, you lose weight, or notice bleeding.

      How fast does achalasia progress?

      Achalasia usually advances slowly: in large studies patients had symptoms for roughly 4 – 5 years before they became severe enough to seek care, and the esophagus often dilates little by little over that time. That said, about 1 in 5 patients report noticeably worse swallowing within a few months, so the pace can occasionally be quicker. Because treatment (balloon dilation, surgical or endoscopic myotomy) can stop further damage, it is best to be evaluated and treated as soon as persistent trouble swallowing solids or liquids appears.

      Is achalasia considered a permanent disability?

      Achalasia itself is a chronic (usually lifelong) condition, but it is only labeled a “permanent disability” if, even after appropriate treatment, your swallowing problems are severe enough to stop you from doing gainful work. Disability agencies look at how much weight you’ve lost, how often food or liquid gets stuck, and whether repeated procedures still leave you unable to maintain nutrition or perform job tasks; some patients qualify, others do not. If symptoms remain significant after therapy, keep detailed medical records and discuss a formal disability evaluation with your gastroenterologist and a benefits specialist.

      What not to eat with achalasia?

      Skip foods that are hard to chew or dry out quickly—think tough red meat, bread crusts, rice, nuts, raw fibrous vegetables, sticky peanut butter, and carbonated or very hot/cold drinks that can spasm the esophagus—because they are more likely to get stuck when the swallowing muscle is weak. Aim instead for soft, moist choices (well-cooked chicken or fish without bones, oatmeal, smoothies, soups) and keep everything well-sauced or blended; test new foods in small bites and adjust with professional guidance, since each person’s “do-not-eat” list is a little different.

      How do you live with achalasia?

      Think of achalasia care in two layers: everyday tactics and specialist treatment. Day to day, eat 5–6 small, soft meals, wash each bite down with liquid, stay upright for an hour after eating, and sleep on an incline to curb night-time regurgitation. Long-term relief usually requires a gastroenterologist to stretch (pneumatic dilation), inject Botox, or cut the tight muscle through POEM or laparoscopic Heller myotomy—procedures that resolve swallowing problems for most people; ask for evaluation if you have weight loss, chest pain, or food coming back up.

      What aggravates achalasia?

      Achalasia symptoms flare when something makes it even harder for food or liquid to pass through the tight lower esophageal sphincter. In practical terms, that often means very dry or tough foods (stringy meat, crusty bread, raw hard vegetables), large or hurried bites, carbonated drinks, very hot or icy liquids, alcohol, and lying down or bending soon after eating—all of which either stick, swell with gas, or increase pressure in the esophagus. Keeping portions small, adding moisture or blending foods, eating slowly while upright, and noting personal triggers in a diary can help you tailor a diet that minimises discomfort; discuss persistent problems with your doctor or dietitian.

      What is the severity score for achalasia?

      Doctors gauge achalasia severity with the Eckardt score: trouble swallowing, regurgitation, chest pain, and weight loss are each rated 0 (none) to 3 (severe) and summed for a total of 0–12. A score of 0–2 signals remission, 3–6 indicates active but moderate disease, and above 6 reflects severe disease; after any treatment, clinicians look for a total ≤ 3 to call it a success. Because it is quick and symptom-based, this score is the standard yard-stick for deciding whether further tests or another procedure is needed.

      Will achalasia ever go away?

      Achalasia very rarely disappears on its own—the nerves that open the valve to your stomach are permanently damaged—so the condition is considered lifelong. The encouraging news is that procedures such as pneumatic (balloon) dilation, surgical or endoscopic myotomy (Heller or POEM), and even Botox can relax that valve and keep swallowing comfortable for 80-95 % of patients for many years, and they can be repeated if symptoms creep back.

      How to stretch the esophagus naturally?

      A scarred or truly narrowed esophagus can only be widened by a doctor during an endoscopic dilation, but you can make swallowing easier at home by strengthening the throat muscles and calming irritation. Under the guidance of a speech-language pathologist, exercises such as the “effortful swallow” (hard swallow of a small sip, 10 times, 2-3 sets daily) plus upright eating, small bites, and good reflux control often reduce the feeling of food sticking. If you have sudden worsening, weight loss, or food gets stuck, skip the exercises and seek medical care right away.

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Transcranial Direct Current Stimulation Clinical Trials

      Top Heart Attack Clinical Trials

      Top Skin Cancer Clinical Trials

      Top Stomach Cancer Clinical Trials

      Top Schwannomatosis Clinical Trials

      Top Cardiomyopathy Clinical Trials

      Top Dyslexia Clinical Trials

      Top Aids Clinical Trials

      Top Keratoconus Clinical Trials

      Top Neuroblastoma Clinical Trials

      Top Pregnancy Clinical Trials

      Top Scleroderma Clinical Trials

      By Trial

      Hyperpolarized [13C] Pyruvate Imaging for Healthy Subjects

      Complex Balance Tasks for Traumatic Brain Injury

      Family-School Partnership Intervention for Autism Spectrum Disorder

      Psilocybin for Low Mood

      Robotic Exoskeleton-Assisted Gait Training for Stroke Recovery

      Darolutamide + ADT for Metastatic Hormone-Sensitive Prostate Cancer

      Botox and/or Esophageal Dilation for Achalasia

      Short vs Standard Antibiotics for Childhood Pneumonia

      Cryocompression + Cilostazol for Gynecological Cancers

      SB-4826 for Non-Hodgkin's Lymphoma

      LLM Tool for Physician Workflow

      Chlorhexidine for Recurrent Urinary Tract Infections

      Related Searches

      Top Primary-progressive-multiple-sclerosis Clinical Trials

      Top Basal-cell-carcinoma Clinical Trials

      Top Dementia-with-lewy-bodies Clinical Trials

      Radiofrequency Ablation for Osteoarthritis Post-Knee Replacement

      Genistein for Amyloid Cardiomyopathy

      Gene Therapy for Retinitis Pigmentosa

      School Programs for Youth Cardiovascular Health

      HRM, FLIP, and Prucalopride for Dysphagia

      EpiCor for Respiratory Symptoms

      Fedratinib for Myeloproliferative Disorders

      Ultrasound Therapy for Opioid Use Disorder

      Ivosidenib + Venetoclax +/- Azacitidine for Leukemia